Jointly creating the future of cell & gene therapy orchestration

Our first open X-CELLerator community event took place on September 23, 2021. We want to thank all of you for your participation and contribution to make this event outstanding and successful.

Furthermore, our experts would like to give an answer to the questions that have not been answered during the Q&A session:

In an Industry full of "(fast) followers": how to motivate manufacturers to join forces in order to work together?

From our point of view manufacturers and their therapies will only be successful if they join forces and aim for industry standards. They need to strive to reduce boundaries and establish a collaborative culture. Employees in hospitals, apheresis centers, labs etc. need to have the possibility to increase their efficiency in order to serve more patients in the next years. Therefore, a harmonized team full of experts is required to ensure scalability. End the end, manufactures will not compete on their individual supply chain setup – they will differentiate based on their therapy and its success. 

------------------

When the throughput of patient batches increases as companies advance in their clinical trials and commercial journey, is this approach of having people "check each shipment from end to end sustainable?

People checking each individual shipment manually from end-to-end will not be sufficient and sustainable in the long-run. However, in the first step we must ensure that no failures occur when a therapy is delivered to a patient. As numbers of therapies and patients are currently still low, we can make use of this situation in order to learn and steadily optimize processes and (IT) infrastrucutre. In the long-term, we need experts who oversee thousand of shipments of different manufactures in a kind of ‘control tower’ and who only interact in case of unforeseen circumstances. Our approach is to increase process efficiency, quality and safety with the combinational use of data, automation and humans.